Findings

What do systematic reviews say?

1,155 questions · 1,191 findings · 195 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 209 · 17.5%GRADE not reported 51 · 4.3%Very low 256 · 21.5%Low 273 · 22.9%Moderate 284 · 23.8%High 118 · 9.9%

Gabapentin vs placebo

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · people with diabetic peripheral neuropathy

1 finding from 1 review

Gabapentin for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1439 participants
Moderate

Continuous chest compression alone vs interrupted chest compression plus artificial ventilation

Neurological function at hospital discharge, measured by cerebral performance category (CPC) · Patients with non‐trauma related out‐of‐hospital cardiac arrest

Continuous chest compression alone showed no clear difference in neurological outcomes at hospital discharge Measured as 'good' or… compared with interrupted chest compression plus artificial ventilation (moderate certainty).

1 finding from 1 review

Continuous chest compression versus interrupted chest compression for cardiopulmonary resuscitation of non‐asphyxial… 2017 · Cochrane Headline outcomes only
RR 1.25 [0.94, 1.66]
1 study · 1286 participants
Moderate

Intervention not reported

Disability: modified Rankin Scale (mRS) A measure of disability, with 6 categories: 0 (no symptoms), 1 (no significant disability), 2 (slight disability), 3 (moderate disability), 4 (moderately severe disability), 5 (severe disability), 6 (dead); ... · adults with stroke

1 finding from 1 review

Yoga for stroke rehabilitation 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Very low

Morphine vs placebo

Any pain‐related outcome (moderate pain improvement) · adults with neuropathic pain

It is very uncertain whether morphine changes any pain‐related outcome (moderate pain improvement) compared with placebo (very low certainty).

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
RD 0.27 [0.16, 0.38]
4 studies · 263 participants
Very low

NSAIDs vs placebo

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with fibromyalgia

It is very uncertain whether NSAID changes moderate pain relief: at least 30% reduction in pain, or PGIC much… compared with placebo (very low certainty).

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 192 participants
Very low

Methadone vs placebo

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain

1 finding from 1 review

Methadone for neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 29 participants
Very low

Sugammadex 2.0 mg/kg vs neostigmine (any dose)

Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

1 finding from 1 review

Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 835 participants
Moderate

Sugammadex 4.0 mg/kg vs neostigmine (any dose)

Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sugammadex (any dose) vs neostigmine (any dose)

Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Human albumin vs placebo or no treatment

Moderate or severe OHSS · women at high risk of OHSS

It is very uncertain whether human albumin changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 0.67 [0.47, 0.95]
7 studies · 1452 participants
Very low

HES vs placebo or no treatment

Moderate or severe OHSS · women at high risk of OHSS

It is very uncertain whether HES changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 0.27 [0.12, 0.59]
2 studies · 272 participants
Very low

Mannitol vs placebo / no treatment

Moderate or severe OHSS · women at high risk of OHSS

Mannitol may leads to lower moderate or severe OHSS compared with placebo / no treatment (low certainty).

1 finding from 1 review

Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
OR 0.38 [0.22, 0.64]
1 study · 226 participants
Low

RhCG vs uhCG

Moderate or severe OHSS · patients with final oocyte maturation triggering in IVF and ICSI cycles

RhCG showed no clear difference in OHSS per woman ‐ moderate to severe OHSS compared with uhCG (low certainty).

1 finding from 1 review

Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles 2016 · Cochrane Headline outcomes only
OR 1.76 [0.37, 8.45]
3 studies · 417 participants
Low

RhLH vs uhCG

Incidence of moderate OHSS · patients with final oocyte maturation triggering in IVF and ICSI cycles

It is very uncertain whether rhLH changes OHSS per woman ‐ Moderate OHSS compared with uhCG (very low certainty).

1 finding from 1 review

Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles 2016 · Cochrane Headline outcomes only
OR 0.83 [0.4, 1.7]
2 studies · 289 participants
Very low

Intervention not reported

Adverse events: a. mild to moderate hypoglycaemia (episodes per participant)

1 finding from 1 review

Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2… 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 760 participants
Low

Intervention not reported

Adverse outcomes ‐ corneal haze score at 12 months (grade 1.0 ‐ more prominent haze that does not interfere with visibility of fine iris details; grade 2.0 ‐ mild obscuration of iris details; grade 3.0 ‐ moderate obscuration of iris and lens; and ... · adult participants (≥ 18 years) with myopia

1 finding from 1 review

Laser‐assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Adverse outcomes ‐ glare and halo scores at 3 months (grade 0 ‐ none; grade 1 ‐ very low; grade 2 ‐ low; grade 3 ‐ moderate; grade 4 ‐ high; and grade 5 ‐ very high) · adult participants (≥ 18 years) with myopia

1 finding from 1 review

Laser‐assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Oxycodone MR vs placebo

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 537 participants
Very low

Oral hydromorphone vs placebo

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Moderate benefit: at least 30% reduction in pain, or PGIC much or very much improved · Adults with chronic neuropathic pain

1 finding from 1 review

Fentanyl for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 163 participants
Very low